Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors

NEXT STORY
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
PREV STORY
Vaccines Market to Soar at 10.7 % CAGR and Hit USD 104.87 Billion till 2027 Backed by Several Immunization Programs Funded by Governments: Fortune Business Insights™
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

U.S. Pet Food Market Analysis and Outlook, 2019-2025 – Rise in the Demand for Pet Food Comprising of Organic Ingredients and Free from Pesticides & Artificial Flavors

author_avatar
NASDAQ Market News

Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Developments

- Achieved Meaningful Progress with Key Clinical Programs - - Anticipate Multiple Data Readouts ...

author_avatar
NASDAQ Market News

Novartis erzielte im ersten Halbjahr eine starke Performance. Die Jahresprognose 2020 für das operative Kernergebnis bzw. den Umsatz wurde am oberen bzw. unteren Ende früherer Voraussagen bestätigt.

author_avatar
NASDAQ Market News